Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
- Poor long term growth as Operating profit has grown by an annual rate 46.93% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -51.08
2
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
HKD 1,473 Million ()
NA (Loss Making)
NA
0.00%
-0.64
-7.77%
1.21
Revenue and Profits:
Net Sales:
20 Million
(Quarterly Results - Jun 2021)
Net Profit:
-63 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-26.46%
0%
-26.46%
6 Months
55.74%
0%
55.74%
1 Year
110.21%
0%
110.21%
2 Years
99.11%
0%
99.11%
3 Years
8.12%
0%
8.12%
4 Years
-45.82%
0%
-45.82%
5 Years
0%
0%
0.0%
Shanghai Heartcare Medical Technology Corp. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
21.89%
EBIT Growth (5y)
46.93%
EBIT to Interest (avg)
-51.08
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.67
Sales to Capital Employed (avg)
0.20
Tax Ratio
13.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.57
EV to EBIT
-10.52
EV to EBITDA
-11.21
EV to Capital Employed
2.75
EV to Sales
28.23
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-26.16%
ROE (Latest)
-8.40%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
301.30
256.70
17.37%
Operating Profit (PBDIT) excl Other Income
8.80
-104.50
108.42%
Interest
1.90
2.40
-20.83%
Exceptional Items
4.70
1.00
370.00%
Consolidate Net Profit
-14.80
-103.90
85.76%
Operating Profit Margin (Excl OI)
-86.40%
-546.00%
45.96%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 17.37% vs 20.63% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 85.76% vs 55.41% in Dec 2023
About Shanghai Heartcare Medical Technology Corp. Ltd. 
Shanghai Heartcare Medical Technology Corp. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






